Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIO-TAILOR
2019-004760-21Phase 2Terminated
- Sponsor
- Fondazione Melanoma
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Fondazione Melanoma. Primary endpoint: Overall response rate. Started Nov 2020; status: terminated.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2019-004760-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004760-21.